Maveropepimut-S for Platinum-resistant Epithelial Ovarian Cancer

Phase-Based Progress Estimates
Platinum-resistant Epithelial Ovarian CancerMaveropepimut-S - Other
What conditions do you have?

Study Summary

This trial is testing a new drug, maveropepimut-S, to see if it is effective and safe in treating ovarian cancer that has come back and is resistant to platinum-based drugs.

Eligible Conditions
  • Platinum-resistant Epithelial Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

0 Primary · 9 Secondary · Reporting Duration: up to 23 months

at 6 months
Progression Free Survival (6m PFS)
up to 13 months
CA-125 Response
Cell mediated immune response
Disease Control Rate (DCR)
Frequency of adverse events
Objective Response Rate (ORR)
up to 2 months
Changes in Tumor Micro-environment (TME)
up to 23 months
Duration of Response (DOR)
Overall Survival (OS)
Progression Free Survival (PFS)
Time to Progression (TTP)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

73 Total Participants · 1 Treatment Group

Primary Treatment: Maveropepimut-S · No Placebo Group · Phase 2

MVP-S + CPAExperimental Group · 2 Interventions: Cyclophosphamide 50mg, Maveropepimut-S · Intervention Types: Drug, Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide 50mg
Completed Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 23 months

Who is running the clinical trial?

ImmunoVaccine Technologies, Inc. (IMV Inc.)Lead Sponsor
10 Previous Clinical Trials
561 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be expected to live for at least 6 months.
You have received ≤ 4 prior lines of anti-cancer therapy for ovarian cancer, including at least one platinum-based therapy.
You have measurable disease with at least one non-target lesion accessible by image-guided biopsy
You are willing to undergo on-treatment tumor biopsy.